ArticleThe British journal of ophthalmology2018
Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial.
Article in The British journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00792922 (Research to Programs for Trachoma Elimination), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research to Programs for Trachoma Elimination: Antibiotic Trial
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Antibiotics for trachoma.The Cochrane database of systematic reviews · 2019Pooled it
- Mass Azithromycin Distribution to Prevent Childhood Mortality: A Pooled Analysis of Cluster-Randomized Trials.The American journal of tropical medicine and hygiene · 2019Pooled it
- Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.Ophthalmic epidemiology · 2019Trial
- Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.PLoS neglected tropical diseases · 2019Trial
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Assessing trachoma elimination progress in districts with persistent trachoma, Western Province, Zambia.International health · 2025Article
- Prevalence of Trachoma following Implementation of the SAFE Strategy in Three Local Government Areas of Taraba State, North Eastern Nigeria.Ophthalmic epidemiology · 2023Article
- Trachoma.Nature reviews. Disease primers · 2022Review
- Modelling trachoma post-2020: opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- The Importance of Failure: How Doing Impact Surveys That Fail Saves Trachoma Programs Money.The American journal of tropical medicine and hygiene · 2020Article
- Efficacy of Mass Azithromycin Distribution for Reducing Childhood Mortality Across Geographic Regions.The American journal of tropical medicine and hygiene · 2020Article
- Effectiveness and safety of azithromycin 1.5% eye drops for mass treatment of active trachoma in a highly endemic district in Cameroon.BMJ open ophthalmology · 2020Article
- Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial.Malaria journal · 2019Article
- Toward the Elimination of Disease: the 2019 Weisenfeld Award Lecture.Investigative ophthalmology & visual science · 2019Article
- Ocular Chlamydia trachomatis infection: elimination with mass drug administration.Expert review of anti-infective therapy · 2019Review
- Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia.PLoS neglected tropical diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND/
aimsThe WHO recommends 3-5 years of annual mass azithromycin distribution with at least 80% treatment coverage to districts with active trachoma prevalence over 10% among children. Here, we assess the efficacy of expanding the coverage target to at least 90% for trachoma control in a mesoendemic region of Niger.
methodsTwenty-four communities were randomised to a single day of azithromycin distribution with a coverage target of 80% of the community or up to 4 days of treatment, aiming for greater than 90% coverage. Distributions were annual and individuals above 6 months of age were treated. Children under 5 years of age were monitored for ocular chlamydia infection and active trachoma.
resultsAt baseline, ocular chlamydia prevalence was 20.5% (95% CI 9.8% to 31.2%) in the standard coverage arm and 21.9% (95% CI 11.3% to 32.5%) in the enhanced coverage arm, which reduced to 4.6% (95% CI 0% to 9.5%, p=0.008) and 7.1% (95% CI 2.7% to 11.4%, p<0.001) at 36 months, respectively. There was no significant difference in 36-month ocular chlamydia prevalence between the two arms (p=0.21). There was no difference in the rate of decline in ocular chlamydia between the two arms in a repeated measures model (p=0.80).
conclusionsFor annual mass azithromycin distribution programme to an entire community, there may be no additional benefit of increasing antibiotic coverage above the WHO's 80% target. TRIAL REGISTRATION NUMBER: NCT00792922, post-results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.